Background Pancreatic cancer is a devastating disease with poor prognosis. It is characterized by a pronounced stromal reaction, which resists chemotherapeutics and eff ective tumor treatment. Pancreatic stellate cells (PSCs) are mainly responsible for this stromal reaction. Moreover, the cancer and stromal interaction seems to promote tumor proliferation. In this study, L49H37, a newly synthesized curcumin analog, was used as intervention to target the stromal compartment of pancreatic cancer.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the 10th most common type of cancer in the world. It is a very aggressive malignant cancer derived from the exocrine part of the pancreas with a dismal prognosis. Due to late diagnosis, related to the usually quite vague symptoms, it is the fourth most common cause of cancer-related deaths in the Western society [1] . Th e overall 5-year survival rate among PDAC patients is less than 5%. PDAC is characterized by a pronounced desmoplastic (prominent fi brotic stroma) reaction. Normal stroma is necessary to provide a connective and functionally supportive framework in the pancreas. With the occurrence of preneoplastic lesions in the pancreas there is an enhanced stromal formation and progression to invasive carcinoma, characterized by a further increase in the dense reactive stroma [2] . Th e neoplastic stroma is very heterogeneous in nature. It is composed of non-cellular and cellular components, such as extracellular matrix (ECM) proteins, growth factors, cytokines, nerve fi bers, various infl ammatory cells, fi broblasts and activated PSCs surrounding the cancer cells, altogether considered to substantially contribute to the aggressive nature of pancreatic cancer, including the metastatic potential and the chemoresistant characteristics of PDAC [3, 4] .
Th e major cellular components of the desmoplastic reaction in PDAC are PSCs and fi broblasts. PSCs are considered as key players in the desmoplastic response in pancreatic cancer. In normal tissue they appear in quiescent fat storing phenotypes expressing intermediate cytofi lamentous proteins, such as vimentin, desmin and glial fi brillary acidic protein [5] . Following pancreatic injury, such as pancreatitis or pancreatic cancer, this quiescent fat storing phenotype PSCs lose their vitamin A droplets and transform themselves into highly activated myofi broblast-like phenotypes, and start expressing α-smooth muscle actin as trans-diff erentiation marker. Th is activated form of PSCs increase their proliferation rate and start producing diff erent growth factors, cytokines, ECM proteins, matrix metalloproteinases and tissue inhibitors of metalloproteinases [6] [7] [8] . Th e similar pathological features were previously described for hepatic stellate cells (HSCs). HSCs and PSCs share numerous characteristics as indicated by morphological, functional and gene expression studies [9, 10] .
Despite some limited improvement over the past decades in the overall treatment of pancreatic cancer, the survival rate of patients with disease progression has not signifi cantly improved. Th e fi rst-line therapy over the years against pancreatic cancer has been gemcitabine, a nucleoside analog, which inhibits tumor growth by blocking DNA synthesis mechanism, although it provides limited survival benefi ts. Hence, there is a need for novel therapeutics, early detection, and chemotherapy strategies to improve survival and render a curative potential in pancreatic cancer [11] .
Curcumin (diferuloyl-methane) is an active constituent extracted from the rhizomes of the turmeric plant (curcuma longa), a yellow color powder commonly used as a spice in Asian cuisines and extensively utilized in ayurvedic herbal remedies [12] . Over the past few decades many scientifi c and clinical studies have focused on the potential of curcumin in treating various diseases due to its pharmacological safety. Curcumin has mainly been investigated for its anti-infl ammatory and anti-oxidant properties. Studies on the anticancer eff ects of curcumin have been conducted, including pulmonary and pancreatic adenocarcinomas, prostate and breast cancer [13] . Curcumin has potent antiproliferative and pro-apoptotic activities, which are exerted through various molecular pathways. It is a well-known inhibitor of nuclear factor-κB, JNK and ERKpathways. Th ese signal transduction pathways also play an important role in PSCs activities [14] . Although this plant-derived curcumin has shown promising anticancer results in in vitro settings, it has poor bioavailability [15] . Hence, we hypothesized that modifi ed curcumin analogs may improve anticancer activity. To test this hypothesis, we have synthesized L49H37, a novel synthetic analog of curcumin in the search for novel therapy alternatives in pancreatic cancer.
In this study, we compared curcumin and L49H37, for their ability of inhibiting and inducing apoptosis in PSCs in vitro at diff erent concentrations as a strategy to target the stromal compartment of pancreatic cancer.
Materials and methods

Cell culture
A conditionally generated, immortalized human PSCs line described previously by Rosendahl et al was used for the experiments [16] . Briefl y, the PSCs were maintained in RPMI1640 (catalog # 21875-034, Gibco-Life technologies, Paisley, UK) supplemented with 10% FBS (catalog # 10270, Gibco-Life technologies, Paisley, UK), Insulin-TransferrinSelenium (catalog # 41400-045, Gibco-Life technologies, Grand Island, NY, USA) and antibiotics (100 U/mL penicillin and 100 μg/mL streptomycin; catalog # 15140-122, Gibco-Life technologies, Paisley, UK) in a humidifi ed 5% CO 2 atmosphere at 33°C. Once PSCs became confl uent, cells were trypsinized and reseeded in fresh fl asks. Aft er 24 h, fl asks were shift ed from 33°C to 37°C and grown to confl uence for an additional 6 days. Th e thermo switching to 37°C switches off T antigen expression, thus causing minimal interference with native cell phenotype.
HL-7702, a human normal cell line was purchased from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (catalog # GNHu 6) and were maintained in RPMI1640 supplemented with 10% FBS and antibiotics.
All experiments were performed in phenol red and serumfree DMEM/Hams Nutrient Mix F12 medium (catalog # 11039-021, Gibco-Life technologies, Paisley, UK), supplemented with penicillin and streptomycin (as above), 2 mM L-glutamine (catalog # 25030-024, Gibco-Life technologies, Paisley, UK), 1.2 mg/mL sodium bicarbonate (catalog# S5761, Sigma, Steinheim, NRW, Germany), 0.2 mg/mL BSA (catalog # A4503, Sigma, Steinheim, NRW, Germany) and 0.01 mg/mL transferrin (catalog # T1147, Sigma, Steinheim, NRW, Germany) serumfree medium (SFM).
Compounds
Preparation of curcumin stock solution
Curcumin (catalog # 28260, Fluka, Steinheim, NRW, Germany) was purchased from Sigma Aldrich. It was dissolved in dimethyl sulfoxide (DMSO) (catalog # D-5879, Sigma, St. Louis, MO, USA) and fi ltered through a 0.2 μm sterile polyethersulfone membrane fi lter (catalog # 514-0073, VWR, USA) and the stock solution was stored at 100 mM.
Synthesis of L49H37
To a stirred solution of 3,4,5-trimethoxybenzaldehyde (156.96 mg, 0.80 mmol) and 1-methylpiperidin-4-one (45.36 mg, 0.40 mmol) in ethanol (10 mL), 40% sodium hydroxide was added drop wise at room temperature. Aft er 10 h, the resulting mixture was diluted with H 2 O (15 mL) and extracted with ethyl acetate. Th e combined organic layers were washed with brine (15 mL) and dried over anhydrous MgSO4, fi ltered, and concentrated under reduced pressure. Th e residue was further purifi ed by chromatography on silica gel to yield 150.24 mg of L49H37 [(3E,5E)-1-Methyl-3,5-bis(3,4,5-trimethoxybenzylidene)piperidin-4-one] as a yellow solid (80%). It was dissolved in DMSO and fi ltered through a 0.2 μm sterile polyethersulfone membrane fi lter and the stock solution was stored at 50 mM.
Th e stability test for curcumin and L49H37 was performed using a reverse phase (High Performance Liquid Chromatography) HPLC (Agilent Technologies 1260 Infi nity, Santa Clara, CA, USA). Briefl y, 20 μL of 1 mg/mL curcumin and L49H37 (dissolved in methanol) were added to 980 μL of 0.1 M phosphate buff er (pH 7.4). Samples were incubated at 37°C for indicated times. Aft er incubation, 200 μL of mixtures were detected by HPLC with a mobile phase of methanol and water.
MTT proliferation assay
Proliferation assay was carried out on PSCs (9×10 3 cells/well) in 96-well plates in growth media for 24 h before switching to SFM for a further 24 h. SFM was added to each well in order to synchronize cells to a resting stage. Cells were subsequently dosed with increasing concentrations of curcumin (0-25 μM) or L49H37 (0-5 μM) in SFM in triplicates. Aft er 24 h of incubation, cell proliferation assay using the MTT; Cell Proliferation Kit I (catalog # 11465007001, Roche, Mannheim, BW, Germany) was performed according to the manufacturer's instructions. Th e absorbance was measured on a Labsystems Multiskan Plus plate reader (test wavelength 595 nm, reference wavelength 660 nm) using the DeltaSoft JV soft ware (BioMetallics Inc., Princeton, NJ, USA).
Th e HL-7702 cells were seeded (7×10 3 cells/well) in 96-well plate in RPMI1640 medium. Th e cells were maintained at 37°C in 5% CO 2 . Cells were incubated with L49H37 for 24 h before the MTT assay. A fresh solution of MTT (5 mg/mL) prepared in NaCl solution (0.9%) was added to each single well of the 96-well plate. Aft er the 4 h of incubation, cells were dissolved with 180 mL of DMSO, and then analyzed in a multi-well-plate reader at 490 nm.
Cell cycle analysis by fl ow cytometer
PSCs were seeded in 6-well culture plates (5.5×10 5 cells/well) for 24 h in growth media and then replaced with SFM for a further 24 h to synchronize the cells. Cells were exposed to increasing concentrations of curcumin (0-25 μM) or L49H37 (0-5 μM) in SFM for 24 h. Both fl oating and adherent cells were collected, fi xed in 70% cold ethanol and incubated overnight at 4°C. Th ereaft er, cells were stained with propidium iodide/ RNAse buff er (catalog # 550825, BD Pharmingen, San Diego, CA, USA), and then cell cycle distribution was analyzed using accuri c6 fl ow cytometer (Catalog # SY-01, BD Biosciences, St. Ives, Cambs, UK). Approximately 20,000 events (cells) were collected for each sample and data analyzed using accuri c6 fl ow cytometer soft ware. Th ree independent experiments were performed.
Western immunoblotting
Cells (5.5x10 5 /well) were grown in 6-well plates for 24 h. Aft er an additional 24 h in SFM, the cells were treated with increasing concentrations of curcumin (0-25 μM) or L49H37 (0-5 μM) in SFM for 24 h, and then lysed on ice for 10 min in lysis buff er (10 mM Tris-HCl, 50 mm NaCl, 5 mM EDTA, 30 mM sodium pyrophosphate, 50 mM sodium fl uoride, 100 μM sodium orthovanadate, 1% Triton X100, pH 7.6) containing protease and phosphatase inhibitor cocktails (catalog # P8340/ catalog # P5726, Sigma-Aldrich, Steinheim, NRW, Germany). Th e protein concentration was determined using BCA protein assay reagent kit (catalog # 23223/ catalog # 23224, Pierce, Th ermoScientifi c, Rockford, IL, USA). Lysates were dissolved in Laemmli buff er, boiled for 5 min and separated by SDS-PAGE (8%) and transferred to 0.2 μm Hybond-C extra nitrocellulose membrane (catalog # RPN303E, Amersham Biosciences, Little Chalfont, BKM, UK). Th e blocked membranes were probed overnight (4°C) with the following antibodies: anti-cleaved poly (ADPribose) polymerase (PARP) (Asp214) (catalog # 9541, Cell Signaling, 1:1000), anti-phospho-p44/p42 MAPK (Th r202-Tyr204) (catalog # 9106, Cell Signaling; 1:2000), anti-GAPDH clone 6C5 (catalog # MAB374, Millipore; 1:1000) and anti-p21 WAF1/Cip1 clone CP74 (catalog # 05-345, Millipore; 1:750). Subsequently, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody and visualized by SuperSignal West Femto Substrate (catalog # 34095, Th ermoScientifi c, Rockford, IL, USA) using LI-COR Odyssey Fc imaging system and Image studio version 3.1 soft ware (Li-Cor, Bad Homburg, HE, Germany).
Statistical analysis
Th e results were expressed as mean ± S.E. (n=3) from at least three independent experiments. Statistical signifi cance was determined by one-or two-way analysis of variance (ANOVA). A P-value of <0.05 was considered statistically signifi cant.
Results
Stability analysis of curcumin and L49H37
Evidence suggests that the active methylene group and β-diketone moiety in curcumin structure contribute to the instability under physiological conditions, which induce rapid degradation and metabolism of curcumin. Th erefore, we have chosen to delete the β-diketone moiety acquiring monocarbonyl analog of curcumin (Fig. 1) , which shows a greater metabolic stability and comparable bioactivity than curcumin (Fig. 2) .
Curcumin and L49H37 treatment reduces PSC proliferation
In the pilot experiments, we have exposed PSCs to the increasing concentrations of curcumin and L49H37. Th e dose response curve was obtained at diff erent concentrations (data not shown) for curcumin and L49H37. Based on these results, we used following doses (curcumin 1, 10 and 25 μM; and L49H37 1, 2.5 and 5 μM) for the subsequent experiments. PSCs proliferation/survival was assessed by MTT assay. Exposure to curcumin (0-25 μM) and L49H37 (0-5 μM) in SFM for 48 h, inhibited the growth of PSCs with increasing concentration (Fig. 3C) .Th e antiproliferative eff ect of L49H37 was much more eff ective than that of curcumin even at lower concentrations of the drug. Th e maximum growth inhibition (65%) for PSCs with curcumin was observed at the highest concentration (25 μM; Fig. 3A) . It was observed that curcumin up to 25 μM did not aff ect the cell viability, but further increase in concentration was found to be cytotoxic (data not shown). On the other hand, 52.2% inhibition was achieved with 2.5 μM of L49H37 (Fig. 3B) , which was ten times less than that of curcumin (25 μM). Th e further increase in concentration (5 μM) of L49H37 did not increase the degree of inhibition. Th e eff ect of L49H37 on HL-7702, a human normal cell line, was observed ( Fig. 1 ; Supplementary data sheet -see online version).
Eff ects of curcumin and L49H37 on the cell cycle
We analyzed the eff ects of curcumin and L49H37 on PSCs cell cycle. Th e cell cycle analysis of PSCs demonstrated (Fig. 4A) that there was an accumulation of cells in G0/G1 phase upon 24 h treatment of both compounds. Th e twoway ANOVA with Dunnett's multiple comparison test was performed and we found that 1 μM (81.8%; P<0.04) and 2.5 μM (83.9%; P<0.001) concentrations of L49H37 resulted in cell arrest at G0/G1 phase compared to control cells in G0/G1 phase (79%), while 25 μM of curcumin arrested the cells in G0/G1 phase (82.6%; P<0.01) (Fig. 4C) .When both treatments were compared, the concentration of L49H37 required was 10 times less than that of curcumin (Fig. 4B) . Th e cell death was also assessed by measuring cleaved PARP, a classical marker for apoptotic cells. Th e curcumin treatment induced apoptosis in PSCs at the highest concentration of curcumin used (25 μM), while more pronounced apoptosis was observed at 2.5-5 μM of L49H37 (Fig. 4D) , which indicates that L49H37 was more potent as compared to curcumin.
Eff ect of curcumin and L49H37 treatment on phospho-ERK1/2
Th e eff ects of curcumin and L49H37 treatment were investigated on growth and survival signaling pathway of PSCs. Th e enhanced proliferative eff ect of PSCs at lower (1 μM and 10 μM) concentrations of curcumin and the lowest (1 μM) concentration of L49H37 showed increased phosphorylation of ERK1/2. However, the highest concentration (25 μM) of curcumin decreased the phosphorylation of ERK1/2. Increasing the concentrations (2.5 μM and 5 μM) of L49H37 signifi cantly reduced the phosphorylation of ERK1/2, indicating its involvement in growth inhibition (Fig. 5 ).
Curcumin and L49H37 treatment downregulates the cell cycle regulatory protein p21 WAF1/Cip1 in PSCs
Aft er curcumin and L49H37 treatments in PSCs cell cycle analysis, it was observed that cells were accumulated in the G0/G1 phase. In this regard, we further examined the major cell cycle transition regulator p21 WAF1/Cip1 aft er 24 h (Fig. 6) . Th e low dose of L49H37 increased the expression levels of p21 WAF1/Cip1 consistent with the increased proliferation observed at this concentration. However, p21 WAF1/Cip1 was decreased with increasing concentration, which explains the increased number of cells in G0/G1 phase of the cell cycle.
Discussion
Th ere are various preclinical studies on curcumin showing that it can modulate the growth of cancer cells through regulation of multiple cell signaling pathways, thereby exerting chemopreventive as well as chemotherapeutic activities in vitro and in xenograft models [17] . In this study, we have investigated the eff ects of curcumin and the curcumin analog L49H37 on PSCs. Both treatments eff ectively inhibited proliferation and induced apoptosis in Figure 1 Deletion of β-diketone moiety from curcumin to acquire mono-carbonyl analog of curcumin (L49H37) PSCs. L49H37 was found to be more potent as much as 10 times at lower concentration than curcumin in the induction of apoptosis, as evidenced by cleaved PARP. Th e cells were retained in the G0/G1 phase of the cell cycle through the downregulation of p21 WAF1/Cip1 . L49H37 signifi cantly decreased the phosphorylation of ERK 1/2, a known regulator of cell proliferation and growth.
PDAC is characterized by a prominent desmoplastic reaction, which recently has been suggested to be involved in chemoresistance in pancreatic cancer [18] . Th ere is increasing evidence demonstrating that the targeting of the stromal compartment of pancreatic cancer may have antitumor eff ects and enhance sensitivity to radiation and chemotherapy. PSCs, the principle source of the stromal reaction in pancreatic cancer, provide a growth permissive niche for cancer cells to grow and spread. Th ere are potential ways to reduce this stromal reaction. It can be achieved by inhibiting the activation and proliferation of PSCs, or by inducing apoptosis in PSCs. Th is depletion of stroma may reduce cancer progression and increase drug delivery into the tumor [19, 20] .
In this study the in vitro antitumor activity of curcumin and its novel synthetic analog L49H37 was investigated against PSCs. It was found that the antiproliferative eff ect of L49H37 (2.5 μM) signifi cantly inhibited the PSCs proliferation as compared to curcumin (25μM). Th is inhibition was observed at about a ten-fold lower concentration, indicating its potency. Prior to apoptotic induction, treatment of curcumin and L49H37 caused a signifi cant cell cycle arrest in PSCs, where cells were arrested at the G0/G1 phase. In eff orts to understand the molecular mechanisms for the cell cycle arrest caused by curcumin and L49H37, we examined changes at cell cycle regulatory protein levels. Th is cell arrest occurred through downregulation of p21 WAF1/Cip1 dependent cell cycle arrest at the G0/G1 phase with increasing concentration. It was previously shown that curcumin induced apoptosis and decreased the expression of p21 WAF1/Cip1 in human colon cancer [21] . It was previously shown in non-small-cell lung cancer cell lines that curcumin treatment has decreased the phosphorylation of ERK [22] and similar kind of eff ect was observed in MDA-MB-231 triple-negative breast cancer cell line [23] . In HSCs, curcumin has been reported to inhibit proliferation and activation by a reduction in ERK [24] . Furthermore, we observed that the highest (25 μM) concentration of curcumin and 2.5-5 μM of L49H37 decreased the expression of phosphorylated ERK, which inhibited the proliferation of PSCs. Th ese results are also in line with previously published results [14] . Th e anti-cancer eff ect of curcumin has been observed in several clinical trials, including pancreatic cancer [25] . Albeit curcumin has an evident anti-cancer activity in humans, rapid degradation and low bioavailability have been put forth as limitations for therapeutic applications. To enhance metabolic stability and pharmacological potency, we synthesized the novel curcumin analog L49H37, a cyclocurcumin resulting in better growth suppressing eff ects and enhanced stability in vitro. Further strategies to improve the biological activity of L49H37 may include the use of drug delivery vehicles, such as nanoparticles to increase circulation times in vivo and increase accumulation in target areas [26, 27] .
To summarize, the present study demonstrated that curcumin and L49H37 inhibit PSC proliferation and induce apoptosis in PSCs through downregulation of p21 WAF1/Cip1 dependent cell cycle arrest at the G0/G1 phase. As a single agent, curcumin exerted its eff ect on PSCs. Th e poor bioavailability and low potency of curcumin when applied in humans limits its potential clinical benefi cial eff ects. Th e L49H37 analog is several times more potent than curcumin. Th us, L49H37 may be a promising therapeutic agent in pancreatic cancer as a single agent, or as part of combination chemotherapy regimens. Additional studies are warranted to further elucidate both mechanisms and eff ects.
Summary Box
What is already known:
• Pancreatic cancer is characterized by a pronounced stromal reaction • Th is stromal reaction promotes tumor progression and contributes to drug resistance • Pancreatic stellate cells (PSCs) are mainly responsible for the excess collagenous stromal deposition
What the new fi ndings are:
• In this study, L49H37, a newly synthesized curcumin analog, was used as intervention to target the stromal compartment of pancreatic cancer • Th e results indicate that the curcumin analog L49H37 exhibits more potent inhibitory eff ects against PSCs than curcumin itself at a lower concentration, and may be used as a novel treatment strategy in pancreatic cancer 
